Request some help to inform NIH researcher Hell
Post# of 148236
Hello Board. I have been in contact with an Alzheimer researcher with the NIH. Interestingly if terrifically annoyingly, she's never thought about Leronlimab. She writes:
"I am not sure how helpful it would be..the compound blocks CC5 [sic], a receptor on the surface of immune cells which can serve as a viral entry site (HIV and COVID-19). I do not immediately see a good application for AD. I have not thought about it at all. I believe there is some cognitive improvement in COVID-infected patients, but that is likely because it has blocked viral entry and reduced infection and its neurological effects."
I know the key is neuroinflammation, which is important in AD, and RANTES is a cytokine and CCR5 a cytokine receptor, and some cytokines help regulate immune cell migration to inflammation sites. But I'm far from a doc, and don't have a good and short knowledgeable quote I can send her that demonstrates that Leron would be good to investigate. She is of course superbusy. Can anyone show me to or offer such a short response? Many thanks in advance.
Just trying to spread the word....